Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Oncotarget|June 18, 2020
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancerAnders Handrup Kverneland, Magnus Pedersen, Marie Christine Wulff Westergaard, et al.
Oncoimmunology|December 8, 2018
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot studyMagnus Pedersen, Marie Christine Wulff Westergaard, Katy Milne, et al.
Cancers|December 23, 2020
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian CancerMarie Christine Wulff Westergaard, Katy Milne, Magnus Pedersen, et al.
Frontiers in Immunology|October 28, 2021
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire <i>via</i> Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-AntigensArianna Draghi, Christopher Aled Chamberlain, Shawez Khan, et al.
Cancers|November 17, 2020
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8<sup>+</sup> T Cells in Non-Melanoma Cancers Compared to MelanomaAishwarya Gokuldass, Arianna Draghi, Krisztian Papp, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Frontiers in Immunology|March 31, 2023
First in man study: Bcl-Xl_42-CAF<sup>®</sup>09b vaccines in patients with locally advanced prostate cancerSofie Kirial Mørk, Per Kongsted, Marie Christine Wulff Westergaard, et al.
Journal for Immunotherapy of Cancer|May 23, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanomaSofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, et al.
Cancer Cell|November 5, 2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationJaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, et al.
Pageof 7